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Human blood agar (HuBA) is widely used in developing countries for the isolation of bacteria from clinical
specimens. This study compared citrated sheep blood agar (CSBA) and HuBA with defibrinated horse blood
agar and defibrinated sheep blood agar (DSBA) for the isolation and antibiotic susceptibility testing of
reference and clinical strains of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.
Reference and clinical strains of all organisms were diluted in brain heart infusion and a clinical specimen of
cerebrospinal fluid and cultured on all agars. Viable counts, colony morphology, and colony size were recorded.
Susceptibility testing for S. pneumoniae and S. pyogenes was performed on defibrinated sheep blood Mueller-
Hinton agar, citrated sheep blood Mueller-Hinton agar (CSB MHA), and human blood Mueller-Hinton agar
plates. For all organisms, the colony numbers were similar on all agars. Substantially smaller colony sizes and
absent or minimal hemolysis were noted on HuBA for all organisms. Antibiotic susceptibility results for S.
pneumoniae were similar for the two sheep blood agars; however, larger zone sizes were displayed on HuBA, and
quality control for the reference strain failed on HuBA. For S. pyogenes, larger zone sizes were demonstrated
on HuBA and CSBA than on DSBA. Poor hemolysis made interpretation of the zone sizes difficult on HuBA.
CSBA is an acceptable alternative for the isolation of these organisms. The characteristic morphology is not
evident, and hemolysis is poor on HuBA; and so HuBA is not recommended for use for the isolation or the
susceptibility testing of any of these organisms. CSB MHA may be suitable for use for the susceptibility testing
of S. pneumoniae.
The culture of organisms such as Streptococcus pneumoniae,
Streptococcus pyogenes, and Staphylococcus aureus remains the
“gold standard” for the diagnosis of serious bacterial infec-
tions. The isolation of some organisms requires a source of
blood as a culture medium supplement. Defibrinated sheep,
horse, pig, or goat blood agar is recommended for the isolation
of S. pneumoniae and S. pyogenes (1, 2, 3, 5). Agar prepared
with human blood is not recommended, partly because of the
safety risk to laboratory personnel, but mainly because it is said
to result in poor bacterial isolation rates, although there are
few published data to support this (2). Despite this, it is com-
mon practice in many developing countries to prepare bacte-
rial culture media by using expired human blood obtained
from donors for blood transfusions, because it is convenient
and inexpensive. For example, human blood agar has rou-
tinely been used in bacteriology laboratories in seven devel-
oping countries that we have recently visited in the Asia-
Pacific region.
Blood must be either defibrinated during collection or col-
lected in bags containing anticoagulant to prevent clot forma-
tion. The most commonly used anticoagulant is citrate phos-
phate dextrose. Citric acid is often used in the food industry to
inhibit the growth of bacteria (8, 9) and is therefore thought to
be unsuitable for use in culture media. Commercial animal
laboratories in developed countries use magnetic stirrers to
defibrinate blood during collection. This specialized equip-
ment is not easily obtained in developing countries, and the
only other option for obtaining large volumes of defibrinated
animal blood is to kill the animal, which is not practical or
acceptable in most countries, and the blood is often contami-
nated. The importation of large quantities of defibrinated
sheep or horse blood or the use of commercially made agar
plates is also not an economically viable option for developing
countries. The noncommercial collection of defibrinated ani-
mal blood requires a sterile glass bottle with glass beads or rods
in situ. The bottle is manually rotated as the blood is collected
so that the fibrin coats the glass beads and clot formation is
prevented; this is also not a practical strategy for the collection
of large volumes of blood.
In Fiji, where human blood agar is used routinely in the
diagnostic bacteriology laboratory, we were unable to establish
a reliable source of defibrinated sheep blood for our research
laboratory. However, we could easily and reliably collect large
volumes of sheep blood in commercially available human
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blood donor packs (which come together with a venipuncture
needle and relevant tubing) containing citrate phosphate dex-
trose. We therefore aimed to compare blood agar prepared by
using citrated human blood, citrated sheep blood, and defi-
brinated, noncitrated sheep blood with commercially available
defibrinated, noncitrated horse blood agar. We tested each of
these agars for their performance characteristics for the growth
and antibiotic susceptibility testing of reference and clinical
strains of S. pneumoniae, S. pyogenes, and S. aureus.
MATERIALS AND METHODS
This study was duplicated at two sites, the Colonial War Memorial Hospital
(CWMH) laboratory, Suva, Fiji, and the Royal Children’s Hospital (RCH),
Melbourne, Australia. Photographs were taken from the RCH results.
Laboratory methods. Each strain was cultured in serial dilutions prepared in
brain heart infusion on each of four agars: defibrinated horse blood agar (HBA;
Oxoid Ltd., Hampshire, United Kingdom), defibrinated sheep blood agar
(DSBA), citrated sheep blood agar (CSBA), and citrated human blood agar
(HuBA) plates. Each dilution of each organism on each blood agar was tested in
triplicate at both laboratories. In an attempt to mimic the isolation of bacteria
from a clinical sample, we repeated the same experiments using serial dilutions
of the same organisms in a sample of sterile cerebrospinal fluid (CSF) obtained
from a patient who had been admitted to RCH for a revision of his ventriculo-
peritoneal shunt. At CWMH, the CSF, obtained from a patient with suspected
meningitis, had a normal appearance by microscopy and no growth on culture.
Finally, we compared DSBA, CSBA, and HuBA for use in antibiotic suscepti-
bility testing for S. pneumoniae and S. pyogenes.
Blood collection and medium preparation. At CWMH, citrated and defi-
brinated sheep blood were collected by an aseptic technique from healthy sheep
who were not receiving antibiotics at the time of blood collection. The defi-
brinated blood was collected in a sterile glass bottle containing glass rods that
were manually rotated. Four hundred fifty milliliters of sheep blood was collected
in a standard, sterile blood donor bag (Baxter Healthcare) containing 63 ml of
citrate phosphate dextrose as an anticoagulant. Following collection, the blood
was immediately chilled and transported to the CWMH laboratory, where 10 ml
of blood was transferred aseptically into BacTalert (Biomerieux, Inc, Durham,
NC) bottles and incubated for 7 days to ensure sterility. Expired human blood
that had been collected from numerous donors in an aseptic manner and that
had been stored at between 2 and 8°C was pooled and obtained from both
hospitals’ blood banks. Fifty-six millimeters of citrated sheep blood was added to
1 liter of agar. The blood agar plates were prepared by standard methods (Oxoid
Australia Pty. Ltd). Columbia (Oxoid Ltd.) agar base was used for initial growth,
and Mueller-Hinton (Oxoid Ltd.) agar was used for sensitivity testing. The agar
plates were stored at 2 to 8°C until they were required.
At RCH, an expired human blood pack containing 63 ml of citrate phosphate
dextrose was obtained from one donor. The citrated sheep blood and the defi-
brinated sheep blood were obtained from a commercial supplier (Institute of
Medical and Veterinary Science, South Australia). The medium was prepared
according to the methods of CWMH (Oxoid Australia Pty. Ltd.). The defi-
brinated HBA was made commercially (Oxoid Ltd.).
Strains and dilutions. Three S. pneumoniae strains were used: strains ATCC
49619 (serotype 19F) and ATCC 6305 (serotype 5) and a clinical isolate (sero-
type 1, isolated from a blood culture). Three S. aureus strains were used: strains
ATCC 25923 and ATCC 29213 and a clinical isolate (isolated from a blood
culture). Two S. pyogenes strains were used: strain ATCC 19615 (emm type 80)
and a clinical isolate (emm type 1, isolated from a blood culture). Each strain was
inoculated in brain heart infusion (Oxoid Ltd.) broth to make a suspension equal
to a 0.5 McFarland standard (1.2  108 CFU/ml). These were serially diluted
before 100 l was plated in triplicate on each agar. Similarly, each strain was
serially diluted in CSF before it was plated in triplicate on each agar. The
inoculated plates were incubated at 35°C in 5% CO2 for 18 to 20 h. The results
were recorded in terms of viable counts, colony morphology (by description and
photographs), and colony size (recorded in millimeters at the widest margin).
Antibiotic susceptibility testing. Susceptibility testing was performed at
CWMH only. Susceptibility testing for S. aureus was not performed, as blood is
not required as a medium supplement for this organism. To test susceptibility, 0.5
McFarland standard concentrations were made in triplicate from S. pneumoniae
strains ATCC 49619 and ATCC 6305 and a clinical isolate from a normally sterile
site and from S. pyogenes strain ATCC 19615 and a clinical isolate from a
normally sterile site. According to the methods of the CLSI (formerly the NCCLS)
(6, 7), each sample was inoculated onto three different blood Mueller-Hinton
(Oxoid Ltd.) plates. Disks containing oxacillin at 1 g, erythromycin at 15 g,
chloramphenicol at 30 g, and co-trimoxazole at 1.25 g (Difco, Sparks, MD) were
applied along with an optochin disk for the pneumococcal isolates. Disks con-
taining penicillin at 1 g, erythromycin at 15 g, chloramphenicol at 30 g, and
vancomycin at 30 g (Oxoid Ltd.) were applied for the S. pyogenes isolates. All
plates were incubated overnight in 5% CO2 at 35°C. Zone diameters were read
following 24 h if incubation. Two scientists read the plates independently.
RESULTS
The results of the isolation of all organisms were combined
and the results from both CWMH and RCH were similar.
S. pneumoniae. The numbers of colonies of the S. pneu-
moniae reference strains were similar on all blood agars at all
dilutions, including the strains in CSF (Table 1). In addition,
the growth of a clinical isolate of S. pneumoniae was similar on
all blood agars at all dilutions and in CSF (data not shown).
The morphological appearances were similar for colonies on
HBA, CSBA, and DSBA. However, colonies were much
smaller and alpha-hemolysis was not obvious for any strain on
TABLE 1. Colony counts of strains tested on four
different blood agar plates
Strain and dilutiona
Colony counts on blood agar plates (range
for triplicate plates)
HBA CSBA DSBA HuBA
S. pneumoniae ATCC 6305
1.4  103 100 100 100 100
1.4  104 1,000 1,000 1,000 1,000
1.5  102 in CSF 100 100 100 100
1.1  104 in CSF 1,000 1,000 1,000 1,000
S. pneumoniae ATCC 49619
2.1  103 100 100 100 100
2.1  104 1,000 1,000 1,000 1,000
1.6  102 in CSF 100 100 100 100
1.6  104 in CSF 1,000 1,000 1,000 1,000
S. aureus ATCC 25923
2  102 18–21 22–29 22–32 13–32
2  104 1,000 1,000 1,000 1,000
1.1  102 in CSF 100 100 100 100
1.1  104 in CSF 1,000 1,000 1,000 1,000
S. aureus ATCC 29213
2.5  102 18–38 9–21 24–28 9–14
2.5  104 1,000 1,000 1,000 1,000
1.6  102 in CSF 100 100 100 100
1.6  104 in CSF 1,000 1,000 1,000 1,000
S. pyogenes ATCC 19615
7  101 6–8 6–22 8–24 1–14
7  103 100 100 100 100
1  102 in CSF 100 100 100 100
1  104 in CSF 100 100 100 100
S. pyogenes strain JC20
1.2  102 6–16 2–15 2–13 12–15
1.2  104 1,000 1,000 1,000 1,000
4.5  101 in CSF 14–20 7–10 10–12 2–6
4.5  103 in CSF 100 100 100 70
a Results are presented for the upper and the lower dilutions only. In many
cases (e.g., for all S. aureus and S. pyogenes strains) intermediate dilutions were
also tested, with identical results for each agar. A clinical isolate of S. pneu-
moniae and a clinical isolate of S. aureus were also tested (results not shown).
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FIG. 1. Growth of S. pneumoniae ATCC 6305 on the four different blood agars at a dilution of 1  101 CFU/ml.
TABLE 2. Appearances of colonies and zones of hemolysis for tested strains on four different blood agar plates
Strain and characteristic a
Appearance of colonies and hemolysis on blood agar plates
HBA CSBA DSBA HuBA
S. pneumoniae ATCC 6305
Colony appearance Shiny, grey Mucoid, grey Dull, grey Dull, grey
Colony size (mm) 1 1 1 Pinpoint
Alpha-hemolysis Small, 1 mm Obvious, 1–5 mm Obvious, 1 mm Absent
S. pneumoniae ATCC 49619
Colony appearance Shiny, mucoid grey Dry, grey Dry, grey Shiny, grey
Colony size (mm) 1 1.5 1 Pinpoint
Alpha-hemolysis Obvious, 1 mm Obvious, 1–5 mm Obvious, 1 mm Absent
S. aureus ATCC 25923
Colony appearance Opaque white glossy Opaque white glossy Opaque white glossy Opaque white glossy
Colony size (mm) 1.5 1.5 1.5 1.5
Beta hemolysis Faint, 1 mm Obvious, 1 mm Obvious, 1 mm Absent
S. aureus ATCC 29213
Colony appearance Opaque yellow glossy Opaque yellow glossy Opaque yellow glossy Opaque yellow glossy
Colony size (mm) 1.5 1.5 1.5 1
Beta-hemolysis Faint, 1 mm Obvious, 1.8 mm Obvious, 1.8 mm Faint, 1 mm
S. pyogenes ATCC 19615
Colony appearance Glossy white Dry grey-white Dry grey Glossy white
Colony size (mm) 1 1–2 1 Pinpoint
Beta-hemolysis Obvious, 5 mm Faint, 1 mm Obvious, 1 mm Absent
S. pyogenes strain JC20
Colony appearance Glossy white Glossy white Glossy white Glossy white
Colony size (mm) 1.5–1.8 1 1 Pinpoint
Beta-hemolysis Obvious, 1–5 mm Obvious, 1 mm Obvious, 1 mm Absent
a A clinical isolate of S. pneumoniae and a clinical isolate of S. aureus were also tested (results not shown).
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HuBA (Table 2; Fig. 1). Additional photographs are available
on the http://www.rch.org.au/cich/pubs/ website.
S. aureus. The numbers of colonies of the S. aureus reference
strains were similar on all blood agars at all dilutions, including
the strains in CSF (Table 1). In addition, the growth of a
clinical isolate of S. aureus was similar on all blood agars at all
dilutions and in CSF (data not shown). The appearances and
the sizes of the colonies were similar on all agars, but hemolysis
was not obvious for any strain on HuBA and was only faint on
HBA (Table 2; Fig. 2). Additional photographs are available
on the http://www.rch.org.au/cich/pubs/ website.
S. pyogenes. The numbers of colonies of the S. pyogenes
reference and clinical strains were similar on all blood agars at
all dilutions, including the strains in CSF (Table 1). The ap-
pearances and the sizes of the colonies were similar on HBA,
CSBA, and DSBA. Hemolysis was most obvious on HBA and
DSBA, although it was still present on CSBA. On HuBA, S.
pyogenes colonies were pinpoint in size and hemolysis was
absent (Table 2, Fig. 3). Additional photographs are available
on the http://www.rch.org.au/cich/pubs/ website.
Antibiotic susceptibility testing results. The antibiotic sus-
ceptibility testing results for S. pneumoniae were similar for
both sheep Mueller-Hinton blood agars, but the human Muel-
ler-Hinton blood agar (Hu MHA) demonstrated larger zone
sizes for all antibiotics (Table 3). The susceptibility reference
strain, ATCC 49619, failed quality control on the Hu MHA
plates. The hemolysis on these plates was subtle, and it was
difficult to discern where growth began.
The antibiotic susceptibility results for S. pyogenes showed
that the citrated sheep Mueller-Hinton blood agar (CSB
MHA) and the Hu MHA plates displayed larger zone sizes
than the defibrinated Mueller-Hinton blood agar (DSB MHA)
plate (Table 4). It was much easier to read the defibrinated and
citrated sheep blood agars due to the hemolysis present. The
Hu MHA plates were difficult to read due to the lack of
beta-hemolysis.
DISCUSSION
The results presented here confirm that although S. pneu-
moniae, S. aureus, and S. pyogenes grow on HuBA, the colony
sizes tend to be very small, the morphology often varies from
that present on animal blood agar, and hemolysis is minimal.
As colony size, colony morphology, and hemolysis are all crit-
ical to the identification of these organisms, there is a much
greater chance these organisms from human specimens cul-
tured on HuBA will be overlooked or misidentified, especially
when other organisms may be present (e.g., for samples from
the upper respiratory tract or skin swabs). HuBA also per-
formed poorly compared to the performance of sheep blood
agar for antibiotic susceptibility testing. These findings have
profound implications for developing countries, where expired
FIG. 2. Growth of S. aureus ATCC 25923 on the four different blood agars at a dilution of 1  102 CFU/ml.
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human blood is commonly used as a medium supplement.
Aside from the implications for clinical care, it is likely that
measurements of the disease burden due to these organisms
are underestimates in countries that routinely use HuBA.
To our knowledge, this is the first time that HuBA has been
shown to be suboptimal for the growth and susceptibility test-
ing of S. pneumoniae, S. aureus, and S. pyogenes. The only
published comparison of HBA, DSBA, and anticoagulated hu-
man blood agar that we could find was a study that compared
the isolation of Bordetella pertussis on different blood agars (4).
That study demonstrated that HuBA was inferior to defi-
brinated horse and sheep blood agar. It is not clear why HuBA
FIG. 3. Growth of Streptococcus pyogenes ATCC 19615 on the four different blood agars at a dilution of 1  102 CFU/ml.




Oxacillin Erythromycin Chloramphenicol Trimethoprim-sulfamethoxazole Optochin
ATCC 6305
CSB MHA 32–35 31–33 32–33 26–32 13–20
DSB MHA 32–33 31–33 30–34 29–32 15–17
Hu MHA 32–39 30–35 30–39 28–40 14–17
ATCC 49619 a
CSB MHA 10–11 28–29 27–29 26–28 10–13
DSB MHA 10–11 27–29 26–27 25–27 10–13
Hu MHA 13–14 30–32 33–36 32–36 10–13
Clinical isolate 42796
CSB MHA 29–33 29–30 29–31 25–28 12–15
DSB MHA 28–31 29–32 29–32 28–31 12–14
Hu MHA 30–35 30–42 32–38 27–38 14–17
a Values are ranges. Acceptable results for CLSI susceptibility quality control: oxacillin, 12 mm; erythromycin, 25 to 30 mm; chloramphenicol, 23 to 27 mm;
trimethoprim-sulfamethoxazole, 20 to 28 mm.
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is inferior to agar with other animal blood. It has been sug-
gested that human blood may contain antibiotics, antibodies,
or other anti-infective agents (5). The lack of hemolysis on
human blood agar may be due to the age of the red cells in the
expired human blood or some other factor.
By contrast, we were able for the first time to describe a
practical alternative to human blood—citrated sheep blood—
that most countries should be able to adapt without requiring
a major investment in infrastructure. Citrate is said to have
antibacterial characteristics (8, 9), but we found that CSBA
performed similarly in most aspects to DSBA. Other studies
have demonstrated that defibrinated pig blood and goat blood
are suitable alternatives for medium supplements for S. pneu-
moniae (1, 3), raising the possibility that citrated blood from
animals other than sheep may also be acceptable. In our ex-
perience, it is the collection of defibrinated blood rather than
the availability of the animal that has posed the most difficult
hurdle in providing a sustainable supply of blood.
We are confident that CSBA may be used for the isolation of
all three organisms tested in this study. Our study evaluated a
citrate to blood ratio of 1:10. It is not known whether a ratio
lower than this may affect the growth and sensitivity pattern of
the organisms; therefore, care needs to be taken at the point of
collection to ensure that the correct ratio of blood is collected.
Hu MHA plates, which are used routinely in developing
countries, cannot be recommended for use for the isolation or
susceptibility testing of any of these organisms, which supports
existing recommendations (1, 2, 3, 5). A strategy is required to
phase out its use. Further work is required to assess whether
CSB MHA is suitable for antibiotic susceptibility testing for S.
pneumoniae. Preliminary data suggest that it is likely to per-
form better than Hu MHA. Our results did not confirm that
CSB MHA plates could be used for susceptibility testing for S.
pyogenes. Further work is required to assess whether CSBA
and CSB MHA are suitable for the isolation and susceptibility
testing, respectively, of a larger range of organisms. This will
determine whether they could be recommended as practical
alternatives for universal use.
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Penicillin Erythromycin Chloramphenicol Vancomycin
ATCC 19615
CSB MHA 38–42 35–36 28 22–23
DSB MHA 32–33 25–27 26–27 22–23
Hu MHA 35–37 24–25 27–28 23–24
JC 20
CSB MHA 33–34 27–29 22–23 20–21
DSB MHA 30–31 24–25 22–23 18–19
Hu MHA 35–36 24–25 22–24 20–22
Clinical isolate
CSB MHA 38–39 28–29 27–28 21–22
DSB MHA 38–40 28 28–29 19–20
Hu MHA 31–34 22–25 27–28 18–21
VOL. 44, 2006 CITRATED SHEEP AND HUMAN BLOOD AGAR 3351
